Testing a targeted medication for children with newly diagnosed brain tumors

This trial is testing a medication called lorlatinib for children and young adults who have been newly diagnosed with a serious type of brain tumor called high-grade glioma. The medication is designed to target tumors that have specific genetic changes (ALK or ROS-1 fusions). Researchers want to learn whether this treatment works, how safe it is, and whether it works better when combined with standard chemotherapy.

High-grade brain tumors in children are serious and hard to treat with standard approaches alone. Some of these tumors have specific genetic changes that the medication is designed to target, offering hope that a more personalized approach might help.